Benefit with cardiac myosin activator in HFrEF - PACE-CME

Benefit with cardiac myosin activator in HFrEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations
Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations
AHA 2020
Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations
- Prof. Piotr Ponikowski, MD, PhD
Strengths and limitations of one-month DAPT trial
Strengths and limitations of one-month DAPT trial
AHA 2020
Strengths and limitations of one-month DAPT trial
- Róisín Colleran, MD
No effect of omega-3 carboxylic acid on MACE in high-risk patients
No effect of omega-3 carboxylic acid on MACE in high-risk patients
AHA 2020
No effect of omega-3 carboxylic acid on MACE in high-risk patients
- Prof. Michael Lincoff, MD
What is the value of a polypill with or without aspirin?
What is the value of a polypill with or without aspirin?
AHA 2020
What is the value of a polypill with or without aspirin?
- Prof. Salim Yusuf